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A B S T R A C T
Nonconvulsive status epilepticus (NCSE) and epilepsia partialis continua (EPC) are common epileptic
conditions for which straightforward recommendations based on controlled randomized trials for
treatment in therapy refractory courses are lacking. In a large retrospective study on drug efﬁcacy in
status epilepticus (SE) we identiﬁed the patients treated in our department by searching for the term
‘‘status epilepticus’’ in the electronic archive of medical reports of our clinic. Here we present the subset
of data concerning the patients treated with lacosamide (LCM). Ten episodes of SE in nine patients could
be analyzed. To control for age dependency of results at discharge we calculated a Spearman correlation
coefﬁcient with age as independent variable and return to baseline Modiﬁed Rankin Score (mRS) at
discharge = 1, worsening of condition at discharge (i.e. new neurological deﬁcit or worsening of mRS) = 2
and death in hospital = 3 as dependent variables. LCM was given in dosages of 50–100 mg. It was not
earlier administered than as fourth drug. Nevertheless it seemed to be effective for termination of status
epilepticus in 20% of the episodes. But the outcome at discharge seemed considerably to depend on age of
patients (r = 0.94, explaining 89% of variance).
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Status epilepticus (SE) is a common medical condition with an
incidence in the Caucasian population of at least 20/100,000/year.1
Whereas in generalized convulsive status epilepticus (GCSE)
guidelines agree that for the treatment of refractory GCSE after
the administration of a benzodiazepine and one other antiepileptic
drug (AED) like phenytoin or phenobarbital anesthesia is required,2
the recommendations for the treatment of nonconvulsive status
epilepticus (NCSE) and simple partial motor status epilepticus or
epilepsia partialis continua (EPC) are not that straightforward.
Especially in EPC any drug effective in chronic epilepsy may be
tried.3 In NCSE with the exception of subtle SE after insufﬁcient
treatment of GCSE after failure of ﬁrst line therapy further non-
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four case reports5–8 and three case series9–11 of patients with
refractory SE or periodic epileptiform patterns treated with
lacosamide (LCM) have been published. In all case reports successful
treatments with LCM were described. Koubeissi et al.10 reported in
their whole group of four patients successful treatments of SE with
LCM. In the series of Kellinghaus et al.9 LCM was the termination
drug in 17 of 39 episodes of status epilepticus. In the series of
Parkerson et al.11 12 of 17 patients responded to LCM with
improvement in the seizures or the epileptiform activity. Here we
present the experience with LCM in the treatment of NCSE and EPC at
the university hospital of Rostock, which may provide further
evidence concerning the efﬁcacy of LCM in these conditions.
2. Methods
The data presented here are part of a large ongoing retrospec-
tive study, in which we evaluate every status epilepticus treatment
at the neurological department of the University of Rostock from
2000 to 2009. This study was approved by the local ethics board at
Rostock University under the identiﬁer A 201002. In this study we
identify the patients treated in our department by searching for the
term ‘‘status epilepticus’’ in the electronic archive of medical
reports of our clinic. Then we review the medical ﬁle of these
patients to make out at which time which AED was administered
and which AED at which time was effective to terminate thevier Ltd. All rights reserved.
Table 1
Patient’s clinical characteristics.
Episode Patient’s
age
Patient’s
gender
Classiﬁcation
of status
Etiology Outcome
1 75 Female 3e Left temporal meningeoma 10 years ago Deterioration of preexisting aphasia
2 75 Female 3e Left temporal meningeoma 10 years ago Deterioration of preexisting aphasia, new tetraparesis
3 81 Female 3d ii Left hemispheric ischemia 3 years ago Death of pneumonia
4 52 Female EPC Right hemispheric ischemia 3 years ago Return to baseline
5 55 Male 3d ii Pneumonia Return to baseline
6 78 Male 3d ii Cerebral metastasis of urinary bladder carcinoma Death of septicemia
7 84 Female 3e New left hemispheric ischemia Death of pneumonia
8 64 Male EPC Right hemispheric ischemic leucencephalopathy Deterioration of general condition (i.e. mRS 4  5)
9 56 Female 3d ii Sinus thrombosis 3 months ago Return to baseline
10 59 Female 3d i HSV 1 encephalitis Return to baseline with deﬁcits due to encephalitis
EPC, epilepsia partialis continua; 3d i, limbic complex partial status epilepticus (Shorvon [13]), 3d ii, nonlimbic complex partial status epilepticus (Shorvon [13]); 3e
nonconvulsive status epilepticus in the postictal phase of tonic-clonic seizures (Shorvon [13]).
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is deﬁned as termination drug, regardless of the latency between
its ﬁrst administration and SE cessation. Cessation of SE is deﬁned
as the end of convulsion in EPC and the return to baseline of
consciousness or the resolution of previously documented
electroencephalographic seizure activity in NCSE. Resolution of
seizure activity was diagnosed when spikes, sharp waves or
rhythmic waveform showed a frequency below 1 Hz without
signiﬁcant evolution in ﬁeld, morphology and frequency.12 As co-
medication of the termination drug all AEDs given during the 24 h
before were listed. Subgroups of NCSE are classiﬁed according to
the system of Shorvon.13 Here we present the subset of data
concerning the patients treated with LCM. To control for age
dependency of results at discharge we calculated a Spearman
correlation coefﬁcient with age as independent variable and return
to baseline Modiﬁed Rankin Score (mRS)14 at discharge = 1,
worsening of condition at discharge (i.e. new neurological deﬁcit
or worsening of mRS) = 2 and death in hospital = 3 as dependent
variables.
The ﬁrst two episodes of this series are published as part of a
case report of a patient presenting three times with an aphasic
status epilepticus after convulsive status epilepticus.15 The main
focus of that paper laid on the diagnostic difﬁculties in differenti-
ating this semiology of NCSE from a postictal deﬁcit.
3. Results
Ten episodes of SE (2 EPC, 8 NCSE) in 9 patients (6 female,
3 male) were treated with LCM. Patients’ age was 67.1 years on the
average (SD 12.4 years). For details of etiology and outcome seeTable 2
Details of lacosamide medication and medication at cessation of status epilepticus.
Episode Place of LCM
administration
Time in hours of
LCM administration
after the onset
of symptoms
Comedication of LCM 
1 4 195 LEV 3000 mg, VPA 2000
2 4 33.5 LEV 3750 mg, CLN 1 mg
VPA 2000 mg, PGB 150
3 11 390 Propofol 2%, LEV 3000 m
4 4 8 VPA 2000 mg, CLN 2 mg
5 12 167 CLN 10 mg/33 h, LEV 30
LZP 2 mg
6 7 372.5 LEV 4000 mg 
7 6 637 LEV 2000 mg, VPA 2400
8 10 40.16 LEV 3000 mg, CLN 1 mg
VPA 3000 mg, LZP 2 mg
9 6 72 VPA 2200 mg, LEV 4000
10 7 165.08 LEV 4000 mg 
CLN, clonazepam; LEV, levetiracetam; LCM, lacosamide; LZP, lorazepam; PGB, pregabaTable 1. The median number of electroencephalograms recorded in
each patient was 6 (range 1–10). LCM was not used earlier than as
fourth drug (median 6.5, range 4–12) and not earlier than 8 h after
onset of symptoms (median 166 h, range 8–637 h). LCM was given
intravenously in dosages of 50 mg or 100 mg as a bolus or 50 mg
twice a day. No symptomatic bradycardia or other major adverse
event was observed. Since most of our patients were in a state of
impaired consciousness minor neurotoxic adverse events cannot
be ruled out. There were no toxic effects on liver function, renal
function or blood cells. In one episode of EPC and one episode of
NCSE LCM was the termination drug (episodes 3 + 4). Three
patients died in cause of medical complications as pneumonia or
septicemia. In one of those patients the NCSE was previously
terminated by LCM. In the two other patients NCSE could not be
terminated. In all other patients LCM with increased dosage was
still a part of the medication at the cessation of SE. For details of
medication see Table 2. In episode 3 propofol was given as
anaesthetic but no burst suppression was reached. Under this
procedure the interictal electroencephalogram was free of
epileptiform patterns but several clinical focal seizures reoccurred
until LCM was added to the medication. There was a highly
signiﬁcant correlation between age and outcome (r = 0.94,
p < 0.00005) explaining 89% of variance. In fact there was a return
to baseline mRS only in patients younger than 60 years, whereas all
patients older than 75 years died (see Fig. 1).
4. Discussion
In our group of patients LCM was the termination drug of NCSE
or EPC in 20% of the episodes. At ﬁrst glance this is not in line withTermination
drug
Comedication of termination drug
 mg CLN 0.75 mg LEV 3000 mg, LCM 50 mg, VPA 2000 mg
,
 mg
PHT 750 mg VPA 2000 mg, LEV 4000 mg, CLN 1 mg,
LCM 100 mg, TPM 50 mg
g LCM 2  50 mg/d Propofol 2%, LEV 3000 mg
 LCM 50 mg VPA 2000 mg, CLN 2 mg
00 mg, LZP 3 mg CLN 10 mg/33 h, LEV 3000 mg, LCM 100 mg
– –
 mg – –
, LEV 4000 mg PHT 1500 mg, LCM 100 mg, VPA 1000 mg,
CLN 1 mg
 mg LZP 2 mg PHT 750 mg, LCM 300 mg, LEV 4000 mg
CLN 4 mg LEV 4000 mg, LCM 200 mg
line; PHT, phenytoin; TPM, topiramate; VPA, valproate.
Fig. 1. Diagram showing the relation between clinical outcome at discharge from hospital and age of 10 patients with NCSE treated with LCM (~: status terminated by LCM;
~: status not terminated or terminated by anticonvulsant drug other than LCM). Outcome was rated as change of modiﬁed Rankin Scale (mRS) score or a new neurological
deﬁcit at discharge from hospital compared to mRS score before onset of status epilepticus.
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reports5–8 only three case series9–11 of patients with refractory SE
or periodic epileptiform patterns treated with lacosamide (LCM)
have been published. Two of the case reports6,7 were included in
the case series by Kellinghaus et al.9 It has to be kept in mind that
according to all established treatment guidelines we did not give
LCM as a ﬁrst or second line drug in status epilepticus. Since the
prognosis of status epilepticus gets worse with each unsuccessful
attempt to treat, our data have to be discussed with regard to the
place of LCM in the treatment strategies of status epilepticus of
other authors. Our successfully treated cases are similar to the case
presented by Turpı´n-Fenoll et al.,8 where a NCSE in a 72-year-old
patient was terminated by LCM 25 mg twice a day additionally to
levetiracetam 3000 mg after the application of oxcarbacepine,
valproate and clobazam had failed. This is the lowest dose of LCM
reported to terminate a NCSE and the authors themselves discuss
that there might have been a remote effect of the previously given
drugs as well. Another case similar to our successfully treated cases
was reported by Chen et al.5 Here EPC was terminated after four
days with LCM 50 mg twice a day after lorazepam and loading with
phenytoin, levetiracetam and valproate had failed. Since treatment
failures are rarely reported as case reports the efﬁcacy of a drug
cannot be established on the basis of case reports of successful
treatments. Koubeissi et al.10 claim that they reviewed all adult
patients treated with LCM for refractory NCSE at their hospital.
They considered each of their four cases as treated successfully.
However in their patient two LCM reduced seizure frequency from
2 to 3 seizures per hour to one seizure every 2 h, which would not
have qualiﬁed for terminating the status in our case series.
Nevertheless LCM was given as third or ﬁfth drug with initial doses
of 50 mg or 100 mg in a group of patients aged 53–79 years and the
condition of all patients somehow improved. This is not in line with
our data, but the case series is rather small. In the series of
Parkerson et al.11 LCM was added as second or third agent in 88% of
the patients. About 70.5% of their patients improved in terms of
seizure frequency or periodic epileptiform activity after adminis-
tration of LCM. But the outcome at discharge was not so good with
four patients being dead and seven being referred to a hospice or a
rehabilitation centre. When calculating a spearman correlation
between age and clinical outcome with discharge to home = 1,
discharge to rehabilitation or hospice = 2 and death = 3 the
correlation is r = 0.43 (p = 0.084), which is not signiﬁcant butmay explain about 16% of the variance. The two patients, who
were treated with LCM as fourth or ﬁfth drug, were between 60 and
75 years old and outcome was discharge to rehabilitation or
hospice. This may be regarded similar to our outcome criteria 2,
which was reached by all our patients with an age between 60 and
75. After all LCM like other antiepileptic drugs may be more
effective when given early in the course of NCSE and then the
inﬂuence of age on outcome may be smaller than in our case series.
Only Kellinghaus et al.9 performed a subgroup analysis concerning
the time at which LCM was administered in the treatment of NCSE.
In their subgroup of patients, where LCM was given as fourth drug
or later, which is comparable to our sample, LCM was the
termination drug in three out of 15 patients, which is exactly
the 20% as in our group. So in our group of patients LCM seemed to
be as effective as in the comparable subgroup of patients in the
case series of Kellinghaus et al.,9 though in their study LCM was
given at least in the double dosage compared to our study. Because
in 2009 no safety data for LCM in higher initial dosages were
available in 2009 we preferred the lower dosages as reported
here. In all publications about LCM in the treatment of SE the
inﬂuence of age was not discussed. Elsewhere a negative inﬂuence
of increasing age on mortality of SE was described several
times.16,17 But the highly signiﬁcant association of outcome with
age in our group of patients is still striking. Due to the small group
of patients this result has to be interpreted with caution. But even
with a small sample of n = 10 the 95% conﬁdence interval of a
correlation coefﬁcient above 0.9 does not reach 0.6.18 Therefore
with a probability of 95% at least 36% of the variance of the
outcome in our group of patients is explained by age. LCM was part
of the antiepileptic medication in all surviving patients and may
have contributed to the cessation of SE even when it was not the
termination drug as deﬁned above. But after all it seems hard to
evaluate the efﬁcacy of a drug in a medical condition, where
outcome at discharge seems to depend considerably on the age of
the patients and not on the therapeutic approach. This has
especially to be kept in mind, when prospective studies concerning
the therapy of refractory NCSE should be developed. Since in all
studies no major side effects clearly attributable to LCM are
reported LCM seems to be well tolerated and therefore LCM seems
to be a useful alternative in the treatment of refractory NCSE or EPC
even when its real efﬁcacy in comparison to levetiracetam,
valproate or phenytoin still has to be established.
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